Advancing WVE-007, an investigational INHBE GalNAc-siRNA designed to induce fat loss while preserving muscle mass. The initiative includes transitioning from Phase 1 single-ascending dose cohorts to the Phase 2a multidose portion of the INLIGHT trial in individuals with higher BMI, as well as planning combination and maintenance trials.

Expected impact: Establish a highly differentiated, once- or twice-yearly dosing profile for obesity treatment that preserves lean muscle mass, addressing a major limitation of current GLP-1 therapies.

Rapidly advancing Wave's proprietary RNA editing platform (AIMers), highlighted by the clinical development of WVE-006 for AATD and the preclinical advancement of WVE-008 for homozygous PNPLA3 I148M liver disease.

Expected impact: Validate Wave's leadership in therapeutic RNA editing and address significant unmet genetic liver and lung disease markets.

Investigating new bifunctional modalities that combine RNAi and RNA editing, or dual RNAi silencing, into a single oligonucleotide construct designed to silence multiple targets or simultaneously edit/upregulate one target while silencing another.

Expected impact: Expand the therapeutic capabilities of the PRISM platform, enabling complex multi-target interventions in a single therapeutic agent.